SCG3

更新于：2025-05-07

基本信息

别名

FLJ90833、SCG3、secretogranin III

+ [2]

简介

Member of the granin protein family that regulates the biogenesis of secretory granules (PubMed:19357184). Acts as a sorting receptor for intragranular proteins including chromogranin A/CHGA (By similarity). May also play a role in angiogenesis. Promotes endothelial proliferation, migration and tube formation through MEK/ERK signaling pathway (PubMed:29154827).

关联

100 项与 SCG3 相关的临床结果

登录后查看更多信息

100 项与 SCG3 相关的转化医学

登录后查看更多信息

0 项与 SCG3 相关的专利（医药）

登录后查看更多信息

131

项与 SCG3 相关的文献（医药）

2025-02-01·Journal of Histochemistry & Cytochemistry

Dominant Expression of Chromogranin B in Pituitary Corticotrophs and Its Putative Role in Interaction With Secretogranin III

Article

作者: Yasui, Tadashi ; Kikuchi, Shota ; Gomi, Hiroshi ; Hosaka, Masahiro ; Torii, Seiji ; Odashima, Koki

Summary Previous studies have suggested that chromogranin A (CgA) is a partner molecule of secretogranin III (SgIII). In mouse pituitary corticotroph-derived AtT-20 cells, SgIII plays a role in sorting CgA/hormone aggregates into secretory granules (SGs). Although CgA expression is equivocal, CgB is clearly detectable in the rat pituitary corticotrophs. Therefore, we hypothesized that CgB shares a function with CgA in pituitary corticotrophs. In the binding assays, CgB, similar to CgA, showed binding activity to SgIII under weakly acidic conditions and in the presence of Ca2+. Considering the differences in animal species, the different abilities of antibodies, and the conditions of tissue fixation and thin sectioning in immunofluorescence histochemistry, we found that CgA was expressed in a small population (approximately 10%), and its expression intensity was weaker than that of CgB (>98%) in rodent pituitary corticotrophs. In addition, similar to CgA, CgB and SgIII were colocalized in adrenocorticotropic hormone (ACTH) granules. The labeling of CgA and CgB was not completely consistent, and CgB colocalized with SgIII in many granules. These results suggest that there are multiple sorting systems for ACTH granules in pituitary corticotrophs and that the SgIII/CgB complex behaves more dominantly than the SgIII/CgA complex, which has somewhat different properties:

2025-01-01·Journal of Diabetes Investigation

Precision medicine in diabetes prediction: Exploring a subgroup‐specific biomarker strategy for risk stratification

Article

作者: Heng‐Huei, Lin ; Chen, Szu‐Chi ; Fan, Kang‐Chih ; Hsu, Chih‐Yao ; Lyu, Ya‐Pin ; Kuo, Chun‐Heng ; Li, Hung‐Yuan ; Juan, Hsien‐Chia ; Yang, Chung‐Yi ; Lin, Mao‐Shin ; Lin, Chia‐Hung ; Yen, I‐Weng

ABSTRACTIntroductionThe early detection of high‐risk individuals is crucial to delay and reduce the incidence of type 2 diabetes. In this study, we aimed to explore the performance of a novel subgroup‐specific biomarker strategy in the prediction of incident diabetes.Materials and MethodsIn the Taiwan Lifestyle Cohort Study, adult subjects without diabetes were included and followed for the incidence of diabetes in 2006–2019. The biomarkers measured included blood secretogranin III (SCG3), vascular adhesion protein‐1 (VAP‐1), fibrinogen‐like protein 1 (FGL1), angiopoietin‐like protein 6 (ANGPTL6), and angiopoietin‐like protein 4 (ANGPTL4).ResultsAmong the 1,287 subjects, 12.2% developed diabetes during a 6 year follow‐up. Blood VAP‐1 was significantly associated with incident diabetes in the overall population (HR = 0.724, P < 0.05), participants under 65 years old (HR = 0.685, P < 0.05), those with a BMI of ≥24 kg/m2 (HR = 0.673, P < 0.05), and females (HR = 0.635, P < 0.05). Blood ANGPTL6 was significantly correlated with incident diabetes in participants aged 65 and older (HR = 0.314, P < 0.05), and blood SCG3 was associated with incident diabetes in those with a BMI of <24 kg/m2 (HR = 1.296, P < 0.05). Two subgroup‐specific biomarker strategies were developed. The gender and BMI‐specific biomarker strategy, using traditional risk factors and blood SCG3 or VAP‐1 in different subgroups, could improve prediction performance, especially the specificity and positive prediction value, compared with the whole‐population strategy using only traditional risk factors or traditional risk factors plus blood VAP‐1.ConclusionGender‐ and BMI‐specific biomarker strategy can improve the prediction of incident diabetes. A subgroup‐specific biomarker strategy is a novel approach in the prediction of incident diabetes.

2025-01-01·Journal of Investigative Dermatology

Identifying Potential Drug Targets for Keloid: A Mendelian Randomization Study

Article

作者: Luo, Xusong ; Wang, Yinmin ; Yuan, Zhaoqi ; Liu, Fei ; Wang, Xiuxia ; Yang, Jun

Keloids are a skin fibrosis disease characterized by troublesome symptoms, a varying degree of recurrence and inevitable side effects from treatments. Thus, identifying their drug targets is necessary. A 2-sample Mendelian randomization analysis was conducted using proteins from the intersection of the deCODE database and "The Druggable Genome and Support for Target Identification and Validation in Drug Development" as the exposure variable. The outcome variable was based on recently published GWAS of keloids. Summary data-based Mendelian randomization and colocalization analysis was employed to distinguish pleiotropy from linkage. Candidate targets underwent drug target analysis. The primary findings were validated through single-cell RNA-sequencing data, Western Blot and immunofluorescence staining on keloids. Seven proteins were identified as potential drug targets for keloids. Among these proteins, Hedgehog-interacting protein, neurotrimin [NTM], KLKB1, and CRIPTO showed positive correlations with keloids, while PLXNC1, SCG3 and PDGFD exhibited negative correlations. Combined with the single-cell RNA-sequencing data, NTM, PLXNC1, and PDGFD were found highly expressed in the fibroblasts. NTM showed a significant increase in keloids as compared to normal scars. In accordance with the analysis, higher levels of protein expression of NTM in keloids compared to normal skin was observed. The identified proteins may be appealing drug targets for keloids treatment with a special emphasis on NTM.

分析

对领域进行一次全面的分析。

或

查看完整样例数据

Eureka LS:

全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步

立即开始免费试用!

智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。

立即开始数据试用!

智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。